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Abstract  
The structure of alpha-fetoprotein (AFP) is presen-ted 
in light of AFP membership and position in the 
albuminoid gene family in comparison to other gene 
family members. Ontogenetic AFP gene expression is 
reviewed considering AFP mRNA presence in various 
tissues at different times during development. The 
multiple molecular variant forms of AFP are discussed 
in relation to published reports of AFP binding proteins 
and cell surface receptors. The atlas further shows AFP 
as a protein consisting of multiple peptide-cassette  
consisting of amino acid (AA) sequence stretches 
matched to peptide segments on prohormones and 
biological response modifier proteins. Such AFP 
peptide segments could potentially serve as delivery 
agents which could target vascular, neuroendocrine, or 
gastrointestinal cells. A discussion follows in which 
peptide epitopes, extracellular matrix proteins, serine 
proteases, extracellular matrix, and cellular adhesion 
AA identity sites on AFP are considered. The AFP 
molecule is also viewed as a carrier/ transport proein 
based on AA sequence comparison of various proteins 
that bind hydropho-bic ligands and heavy metals 
similar to AFP binding of such components. An 
analysis of trans-cription factors, tumor suppressors, 
and AA-rich motifs follows, interfaced with 
dimerization and nuclear localization sequence matches 
identified on the AFP molecule. Emphasis is further 
placed upon homeodomain and apoptosis AA sequence 
identi-ties given that AFP serves as a fetal, phase-
specific protein throughout embryogenesis, 
histogenesis, and organogenesis. AFP AA sequences 
are further presented as peptide identification sites for 
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growth factors, receptors, cytoskeletal proteins, and 
chemo-kines. A closing discussion summarizes the 
multi-ple and varied motifs of peptide sequences 
matched to AAs on each of AFP's three domains. This
study indicates that short peptide segments, in addition 
to full-length AFP, and domain and subdomain 
fragments of AFP, could be employed as functional 
agents to help unravel the complexity of biological 
roles ascribed to human AFP. 
I. Introduction 
Human alpha-fetoprotein (HAFP) is a single-chain 
glycoprotein with a molecular mass of 69 kDa or 
greater depending on carbohydrate (glycan) content 
(Crandall, 1981; Mizejewski, 1985; Deutsch, 1991). 
HAFP, a tumor-associated fetal protein, is classified as 
a member of a three-domain albuminoid gene family 
that consists of four members: albumin (ALB), 
vitamin-D binding protein (DBP), AFP, and alpha-
albumin (α-ALB) (McLeod and Cooke, 1989; 
Lichenstein et al., 1994) (Figure 1). Similarly to ALB, 
HAFP is known to bind and transport a multitude of 
ligands, including bilirubin, fatty acids, retinoids, 
steroids, heavy metals, dyes, flavonoids, 
phytoestrogens, dioxins, and various organic drugs 
(Mizejewski, 1995a, 1997). Unlike ALB, high 
concentrations of hydrophobic ligands (i.e., fatty acids, 
estrogens) have been reported to induce multiple 
conformational transition forms, which are reversible, 
in the tertiary structure of HAFP (see ref. (Mizejewski, 
2001a) for review). Discordant HAFP levels have long 
been associated with aberrant growth conditions, and it 
was assumed that these AFP levels were coincident 
events, rather than the cause of such malformations. 
Although AFP may not be the direct cause of the 
altered growth structures observed in birth defects, the 
belief is held that some shock/stress-induced 
conformational (variant) forms of this fetal protein may 
influence, modulate, or contribute to such events 
(Mizejewski, 2001a). Over the last two decades, repo ts 
have emerged that some of these HAFP forms can 
serve as dual regulators of growth, capable of either 
enhancement or inhibition of growth, in cancer as well 
as fetal cells (Mizejewski, 2002; Semenkova et al.,
2003). Furthermore, AFP has been reported to promote 
growth via the protein kinase A pathway (Li et al., 
2002b). The growth regulatory properties of HAFP are
one of the more notable features that distinguish this 
fetal protein from adult or fetal serum ALB. 
Objectives:  
At present, there are only a few published reports that
have attempted to map the many structure/ function 
sequences identified on the entire HAFP amino-acid 
sequence (Mizejewski, 2001a; Terentiev and 
Moldogazieva, 2006, 2007). This atlas will survey the 
structure/function peptide sites on HAFP that have 
been identified over the last two decades in addition o 
the most recently discovered protein peptide sites. Fir t, 
the structure of HAFP will be presented as a member of 
the albuminoid gene family. Second, the relationship of 
AFP's biological activity to the naturally occurring 
genetic and structural variant forms of AFP will be
presented. Third, the multiple names and sites of the 
functional motifs discovered on HAFP will be 
presented in illustrated forms together with a narrative 
that attempts to link AA structural findings with 
physiological activities. The present atlas is intend d to 
largely serve as a compendium source that maps most 
of the functionally-known and proposed active sites on 
the entire AA sequence of HAFP, an established 
biologic response modifier (Mizejewski, 1997). Since 
the present review may not be inclusive for all 
physiological activities of AFP, the reader is directed to 
earlier papers that cover these multiple biological 
functions (Uriel, 1989; Deutsch, 1991; Nunez, 1994; 
Mizejewski, 2001a, 2002). 
II. The Albuminoid Gene Family 
AFP, as a member of an albuminoid gene family, is 
structurally characterized by 32 cysteine residues that
result in folding of the polypeptide chain into layers 
that form loops dictated by disulfide bridging; this 
results in a triplet domain, V-shaped molecular 
structure (McLeod and Cooke, 1989; Lichenstein et al., 
1994) (Figures 1, 2). The three domains of AFP and the 
ALB gene family members have been confirmed by X-
ray crystallography, electron dot imaging, and helix-
ribbon modeling (Luft and Lorscheider, 1983; Carter 
and He, 1990) (Figures 1, 2). The albumin gene family 
members share structural similarities, homologous AA 
sequence stretches, and reflect similar cysteine 
disulfide bridge cluster patterns (Figure 1 and Table 1). 
In humans, the four albuminoid genes lie in tandem on 
chromosome 4 within the 4q11-q22 region, 
encompassing 15 exons and 14 introns (Yang et al., 
1985). The Gc-protein alone is truncated in the third 
domain (see dotted square in Figure 1B) and contains 
only 13 exons, which results in a protein with a lower 
molecular mass (Ray et al., 1991). The newest member 
of this gene family, α-ALB, was discovered in both 
rodents and humans and has been cloned in the last 
decade (Belanger et al., 1994; Allard et al., 1995).  
All gene members are capable of ligand/carrier 
transport function, but display a vast array of other 
functions, including chemotaxis, oxygen free radical 
scaveng-ing, esterase activity, leukocyte adhesion, 
copper-stimulated lipid peroxidation, and fatty acid, 
heavy metal, and actin binding, among others 
(Gutteridge, 1986; Constans, 1992; Nathan et al., 
1993).  
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Although the function of the recently discovered αALB 
remains obscure, it may play a role (vitamin-E binding 
and immunoregulation) similar to its orthologs in lower 
vertebrates, a 74 kD albumin-like molecule found in 
fishes, sharks, amphibians, and reptiles (Ohkawa, 1987; 
Butterstein and Mizejewski, 1999). 
III. Genetic Variants 
The genetic variants of mammalian AFP have been 
studied primarily in the rodent and to a lesser extent in 
humans (Table 2). The major fetal and tumor-derived 
mammalian AFP mRNA consists of a 2.2 kilobase (kb) 
transcript that translates to 68-72 kD molecular forms 
in humans and rodents, depending on its carbohydrate 
content (Petropoulos et al., 1983; Petropoulos et al., 
1985). The 1.35 kb AFP mRNA found in adult rat liver 
and kidney deserves special mention, in that a similar 
transcript has been detected in human embryonal 
carcinomas trans-planted into nude mice (Morinaga et 
al., 1982). In both species, a 1.35 kb form is retain d 
intra-cellularly as a non-secreted form previously 
described for uterine and cancer cells (Smalley and
Sarcione, 1980; Sarcione and Hart, 1985). This variant 
represented only 40% of the normal human  
AFP molecule translated from the 2.2 kb mRNA; it 
lacked the entire first domain and one-third of the 
second domain. It may be of interest that certain orphan 
steroid receptors, which dimerize with other nuclear 
receptors, have similar truncated structures 
(Mizejewski, 1993; Seol, 1998; Resnick et al., 2000). 
In this form, truncated AFP variants could potentially 
dimerize with steroid receptors as previously proposed 
in computer models (Mizejewski, 1993). 
The adult form of human AFP, like the rat forms, might 
also be derived from multiple RNA transcripts (i.e. 2.2, 
1.7, 1.6 kb). It is well established that the classical form 
of human AFP detected in most RIAs and EIAs 
represents the 69,000 kD (2.2 kb) polypeptide. It is 
highly probable that other AFP mRNA transcripts exist 
and are translated in cells and/or tissues but are 
undetectable by present-day immunologic assays (see 
below). Although isolation and characteriza-tion of 
these predicted forms are difficult to measure due to 
their vanishingly small concentra-tions, i.e. nanogram 
to picogram levels, recombi-nant PCR technologies 
could someday aid in resolving this issue. 
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IV. Structural Variants 
Molecular variants of HAFP have been known in the 
scientific literature since the 1970-1980 era (Sarcione 
et al., 1983; Sarcione and Biddle, 1987). Initially, some 
of the different forms have been attributed to 
carbohydrate microheterogeneity and variations in 
isoelectric points (Smith and Kelleher, 1980; Crandall, 
1981). Some AFP isoforms were lectin glycoforms that
were detected and isolated by isoelectric focusing, 
electrophoresis, and chromate-graphic methods 
(Breborowicz, 1988; Taketa et al., 1998). Other 
isoforms were detected following high-pressure liquid 
chromatography (HPLC), and lectin, heavy metal, and
hydrophobic solid phase separation methods. The 
advent of monoclonal antibodies further permitted the
detection and analysis of the epitopic domains and 
subdomains that comprise the total antigenic sites of 
this fetal protein (Karamova et al., 1998; Yakimenko et 
al., 1998). Finally, the discovery and characterization 
of the molten globule forms of HAFP have provided a 
new level of understanding regarding the various 
intermediate transition forms of the fetal protein 
(Bychkova, 1993) 
A variety of molecular variants of HAFP have further 
been reported as a result of clinical assays which 
detected aberrant molecular forms of the fetal protein. 
Several such reports of aberrant AFP molecules first 
appeared in the clinical cystic  
fibrosis (CF) literature resulting in confusion of the 
clinical usefulness of AFP for this genetic disorder 
(Table 3). In the 1970s and 1980s prior to the 
development of monoclonal antibodies, polyclonal 
antibody assays for AFP were not as precise and 
sensitive as today's immunoassays. Such factors 
resulted in disparate baseline levels of HAFP in the
sera of non-CF and normal adult patients which ranged 
in concentrations from 5-30 ng/ml. To add to the 
complexity, a previously reported cationic migrating 
form of HAFP was determined to be HAFP complexed 
with IgM molecules; this cationic form has now been 
described in several reports (Mizejewski, 1997, 2001a, 
2002; Beneduce et al., 2004). Additional aberrant forms 
of HAFP have also been detected in fluids found in the 
reproductive/and urinary tract of various clinical 
patients (Lippes et al., 1983), and in the tissues and sera 
of patients bearing breast cancer (Sarcione et al., 1983; 
Sarcione and Hart, 1985; Sarcione and Biddle, 1987). 
A non-secreted form of HAFP, lacking the N-terminal 
signal sequence segment, was also reported in 
recombinant AFP studies employing yolk sac tumors 
(Fukasawa et al., 2005). Furthermore, truncated forms 
of HAFP (~50 kDa) have been detected in cell cultures 
comprised of hepatomas, testicular embryonal 
carcinomas, and breast tumors (Mizejewski, 2002). 
Variant forms of HAFP transcripts from non-translated 
regions of the AFP mRNA have recently been reported 
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in CD34+ hematopoietic progenitor cells derived from 
mesodermal germ cells (Kubota et al., 2002). These 
latter investigators described two variant forms of 
HAFP mRNA that were not expressed in mature adult 
cells. The variant AFP mRNAs differed from the 
authentic AFP mRNA transcripts by incorpora-ting 
exons from the 5'-untranslated region of the HAFP 
gene. The abnormal AFP transcript was found only in 
bone marrow, thymus, and brain tissue. The various 
folding intermediate forms of HAFP have further been 
investigated using bacterial and yeast recombinant 
methodology (Yazova et al., 2003; Leong and 
Middelberg, 2006). The folding of both glycosylated 
(yeast) and non-glycosylated forms of recombinant 
HAFP was studied following protein purification from 
aggregation-prone E. coli inclusion bodies. After AFP 
was denatured, it readily refolded under dilution, redox 
reactions, and ELISA assay conditions in both 
recombinant produced AFP forms. In summary, the 
denaturation of recombinant-derived HAFP was found 
to be a reversible process independent of its source of 
origin, fatty acid relationship, and glycosylated state. 
V. Biological Activities of AFP: Mapping 
of Structure/Function Peptide Sites 
The many and varied biological activities of HAFP 
reported in the biomedical literature have been studied 
for many years (see (Crandall, 1981; Mizejewski, 1985; 
Deutsch, 1991; Mizejewski, 1997, 2001a, 2002)). Such 
functional activity sites of HAFP have included: a)
immunoregulation and peptide epitopes; b) 
extracellular matrix binding and cell adhesion; c) 
enzyme-related modulation; d) transcription 
factor/homeodomains; e) apoptosis-associated 
activities; f) hydrophobic, ion, and metal ligand 
binding; g) hormone and growth factors; h) cell surface 
receptors; i) dimerization and nuclear localization 
signals; j) AA rich repeat sequences; k) cytoskeletal 
proteins, filaments, and microtubules, and l) multiple 
chemokine sites. In the remainder of this atlas, the 
discussion and mapping of the above protein sequences 
specific peptide sites on the AFP molecule will be 
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Multiple AFP AA sequence matching searches were 
performed using the GenBank database derived from 
GCG (Wisconsin Program) software. The identity and 
similarity of the various protein sequences matched in 
the GCG-GenBank database were detected using the 
protein FASTA program. To determine the significance 
of the match, FASTA employed a Z-score algorithm in 
order to evaluate identity/similarity relationships 
between protein and/or peptide AA sequences. For 
comparison between short peptide sequences (less than 
40 AA), a wordscore of 1 to 2 is employed with a 
default set at 2.0 and above. Having set the wordsce, 
an E-value between 1 and 10 is considered statisticlly 
significant. Significant search results were then 
recorded and tabulated. Only identity/similarity 
matches totaling 30% and above are presented. 
A) Immunoregulatory Sites and AFP Peptide 
Epitopes 
The major histocompatibility proteins: The major 
histocompatibility complex (MHC) genes encode three 
major sets of molecules; the class I, II, and III proteins. 
The Class-I proteins address the adaptive and innate 
immune systems employing CD8 cytotoxic T-cells 
(CTL), while Class II molecules are involved in 
immunological recognition as the major 
histocompatibility complex (MHC)-restricting CD4 
helper (Th) cells; Class III molecules are concerned 
with the complement cleavage (lysis) cascade in the 
inflammatory response. While the antigen receptors 
expressed by B lymphocytes can recognize all types of 
antigens, most T-cells recognize peptides that are 
bound to class I or class II cell surface proteins are
encoded by genes in the MHC protein family (Yamada 
and Hayami, 1983). Thus, T-cell class I recognition is 
largely confined to antigenic peptide fragments that are 
bound to the antigen presenting cells (APC) surface 
MHC proteins (Figure 3). A well-characterized 
activation signal for regulated secretion by T-cells 
(cytokines, granzymes, etc.) is engagement of the T-
cell receptor (TCR) by peptides bound to MHCs on the 
surface of APCs during T-cells activation (Johnson et 
al., 2000) (Figures 3, 4). In a similar fashion, the MHC 
class II proteins encompass a great variety of proteins 
that serve to present antigenic peptides to CD4(+) 
helper T-cells (Kawai, 2007). In a classic immune 
response to class-II antigens, naive effector T-cells 
differentiate in two types of CD4 helper cells that c n 
respond to foreign antigens. The first type, the T-helper 
type-1 (Th1) cells act to clear intracellular pathogens, 
while the second cell type, T-helper type-2 cells (Th2), 
control parasitic infections (Hanke et al., 2002). More 
recently, a third class of T-helper cell is induced by 
interleukin-17 and responds to autoimmune tissue 
injury and is referred to as Th17 cells (Ayaru et al.,
2007). 
Major Histocompatibility Complex (MHC) Class 
Proteins: 
The MHC class I molecules are essential for the 
functions of both the adoptive and innate immune 
response systems (Sherman, 2001). The MHC class I 
molecules are sub-divided into two groups, the class I  
and the class Ib types. The highly polymorphic MHC 
class Ia molecules have a seminal role in adaptive 
immunity, while MHC class Ib molecules display more 
limited forms and regulate innate immunity 
encompassing pathogens and tumors. The MHC class 
Ia molecules, termed human leukocyte antigen (HLA)-
A, HLA-B, HLA-C, and HLA-DR are glycoproteins 
that present bound antigenic peptides to receptors 
expressed by T-cells. The class Ia molecules are multi-
chain complexes which consist of a B2-microglobulin 
(B2-M) that is non-covalently associated with a heavy 
chain (Figure 2). The Ia heavy chain contains the 
antigen-binding clefts that serve as anchor points to 
typically bind short peptides of 8-9 AAs (Table 3) in 
length (Terabe and Berzofsky, 2007). 
The multivariate docking sites of the MHC class Ia 
molecules are localized within peptide antigen-binding 
clefts of the APCs which accommodate the 
presentation of a large number of antigenic peptides 
which can bind to clusters of co-segregating class I  
molecules (Figures 3, 4). The selection of antigenic 
peptides (8-10 AAs) that bind within the class Ia cleft is 
usually determined by two binding pockets that specify 
the primary anchor AA (AA) sites, with one or more 
secondary anchor sites that fine-tune the peptide 
binding motifs (Figure 4, Table 3).  
In contrast, the MHC class Ib molecules (including 
NKC receptors) often possess a larger number of 
primary anchor sites that are common to some class Ia 
molecules (Sherman, 2001). The differences in the 
peptide-binding repertoires between class Ia and class 
Ib appears to reflect the different roles of the two 
classes in the immune response. 
HAFP Homologies: Identities and Similarities: 
HAFP displays a MHC class I AA identity peptide site 
on its second domain (Figure 4A) which overlapped an 
antigenic epitope. This AA sequence stretch was 23 
AA long (AA313-336) with an AA identity (ID) of 
39% and a similarity (Sim) of 56%. Class-II proteins 
consist of two noncovalently clustered peptides that 
traverse the plasma membrane at their COOH terminus. 
HAFP also displays a MHC Class-II identity site (AA 
#25-50) on domain I (Figure 4A). This AFP site 
demonstrated a 33% identity stretch (Sim = 52%) over 
25 AA. Finally, the class II molecules (complement-
associated) displayed AA identity sites on HAFP 
within all three AFP domains (see light gray-shaded 
areas, Figure 5A). The Class-III AA identity sequenc s 
ranged from 50-60% and were 62% identical over AA 
lengths from 10-12 AA residues.  
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Based on these sequence homologies, it is tempting to 
speculate that HAFP may be involved (as a mimic or 
soluble receptor) in the immunoregulation of natural 
killer, MHC, and complement interactions at the onset 
of pregnancy, throughout gestation, and possibly in the 
neonatal/infant period (see below). 
The T-cell receptors: 
The immune system is able to distinguish non-self 
pathogens from self-proteins/tissues and this 
discrimination is mediated by the T-cell receptor 
(TCRs) family of proteins (De Mees et al., 2006). The 
TCRs recognize antigenic peptide fragments (epitopes) 
that are attached, bound, and displayed by the MHC 
molecules on the surface of the APCs (see Figure 3A 
bottom). The peptide-bound MHC cluster binds to a 
groove localized on the TCR molecular surface 
(Figures 3, 4). These peptide epitopes are generated by 
the proteolytic degradation of self or foreign proteins 
within cells expressing MHC class I or II molecules in 
a process known as antigen presentation (Dauphinee 
and Mizejewski, 2002). The T-cell recognition of 
foreign peptides is vital for defense against invading 
micro-organisms; however, recognition of self-peptides 
could lead to autoimmune disorders resulting from 
mutation accumulation, aging, disease, and 
viral/bacterial infections. Thus, the boundaries 
separating foreign, self, and altered self-peptides can be 
overlapping and it has been reported that viral/bacterial 
peptides are able to mimic self-peptides (Vakharia nd
Mizejewski, 2000; Harrington et al., 2005). 
The MHC proteins participate in antigen presentation 
via a three-way interaction involving the T-cell 
receptor (TCR), MHC molecules, and APC-processed 
(peptide) antigens (Figure 3). The T-cell receptors 
include multiple types composed of heterodimer 
combinations of α-, β-, γ-, or δ-chains, consisting of 
constant and/or variable chain regions. Both rodent and 
human AFP have been previously implicated in the 
regulation of immune responses of both humoral and 
cell-mediated types (Monaco et al., 1990; Butterfield et 
al., 1999; Cavin et al., 2004). Thus, it was not 
surprising that HAFP AA identity segments involving 
TCRs were detected on all three domains (Figure 5A).
HAFP domain I bears a β-chain TCR site that 
overlapped an AFP epitope site and exhibited a 19-AA 
stretch bearing 39% identity, and Sim = 33% (AA 
#156-175); while the domain II site possessed a 19-AA 
sequence with a 47% identity, and Sim = 21%.  
HAFP domain II revealed a double site consisting of a 
27-AA sequence length with a 41% identity (Sim = 
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25%) (AA #260-287). Finally, the third domain of 
HAFP demonstrated the presence of two identity sites 
composed of shorter AA sequence lengths representing 
the δ-chains of the TCR (AA #472-484; and AA #497-
521), which displayed 40% identities over a 12-24 AA 
lengths (Figure 5A). 
 
AFP Peptide Epitopes and the MHC Proteins: 
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As shown above, AFP-derived peptide epitopes can be 
recognized by heterologous human T cells in the 
context of MHC class I antigens (Mizejewski, 2009). 
Researchers have now determined the identity of 
additional AFP-derived peptides, 8-9 amino-acids in 
length, presented as HLA-A*0201 restricted antigens, 
that could be recognized by the human T cell repertoir  
(Butterfield et al., 1999) (Table 3). After screening 74 
peptides, one research group identified 3 new AFP 
epitopes, HAFP AA #137-145, HAFP AA #158-166, 
and HAFP AA #325-334, in addition to the previously 
reported HAFP AA #542-550 epitope (Figure 5A). 
Each peptide possessed an anchor hydrophobic AA 
residue at each end of the 8-9 mer peptide, and each
stabilized HLA-A*0201 antigens on T-cells in a 
concentration-dependent MHC class I binding assay 
(Table 3). The AFP peptides showed stability for 2-4 h 
in dissociation-kinetic assays. The peptides also 
induced epitope-specific primed T-cells in vitro from 
several normal HLA-A*0201 donors. Importantly, the 
HAFP peptide-specific T-cells also were capable of 
recognizing HLA-A*0201(+)/AFP(+) tumor cells in 
both cytotoxicity and IFN-gamma induction assays. 
The immune-genicity of each peptide was assayed in 
vivo with HLA-A*0201 in Kb-transgenic mice 
following immunization with each peptide emulsified 
in adjuvant; also, draining mouse lymph node cells 
were shown to produce IFN-gamma cytokines on 
recognition of cells stably transfected with HAFP. AFP 
peptide-specific T-cells were also identified in the 
spleens of mice immunized with dendritic cells 
transduced with an AFP-expressing adenovirus 
(AdVhAFP). Three of the four AFP peptides were 
identified by mass spectrometric analysis of cell 
surface peptides derived from an HLA-A*0201 human 
HCC cell line. In summary, the authors presented the 
first and compelling immunological and 
physiochemical evidence which showed that four or 
more HAFP-derived epitopes were immunogenic, 
naturally processed, and presented in the context of 
MHC class I antigens. These investigators confirmed 
that such AFP epitopic sites could serve as prime 
targets for hepatoma immunotherapy (Butterfield et al., 
2001). 
The immune response of lymphocytes was further 
studied after activation of dendritic cells (DCs) 
sensitized by a cytotoxic T lymphocyte (CTL)-based 
peptide from the second domain of human alpha-
fetoprotein (HAFP AA #218-226 LLNQHACAV) 
(Figure 5A). High purity DCs were obtained from 
plastic-adherent monocytes cultured from healthy 
human donors of HLA-A2(+) peripheral blood which 
had been co-incubated for seven days with granulocyte-
monocyte colony-stimulating factor (GM-CSF) and 
interleukin-4 (IL-4). Self-lymphocytes were also 
stimulated with DCs treated with the HAFP AA #218-
226 peptide in a culture medium containing 
interkeukin-2 (IL-2) for 7 days. IL-12 and TNF levels 
were analyzed in culture medium and specific lysis 
activity of lymphocytes was assayed against four 
strains of primary hepatocellular carcinoma cells. After 
stimulation by DCs that were activated with HAFP 
#218-226 peptide, lymphocytes appeared unchanged 
and the culture medium of the activated lymphocytes 
contained high levels of Th1-type cytokines namely, 
IL-12 and TNF. Activated lymphocytes not only 
specifically lysed HLA-A2(+) HepG2 tumor cell line, 
but also showed cytotoxicity against three other 
primary hepatocellular carcinoma cell lines and against 
T2 hepatoma target cells activated with the HAFP 
peptide. The results of these experiments provided th  
underpinnings for developing a DC-based vaccine with 
a HLA-A2 restricted peptide epitope derived from an 
HAFP epitope directed against AFP positive primary 
HCC cells (Deng and Mariuzza, 2007). 
B) Extracellular Matrix, Integrins, and Cell 
Adhesion Molecules 
The major classes of molecules that regulate cellular 
development and physiology include growth and 
differentiation factors, cell adhesion molecules, and 
components of the extracellular matrix (ECM). 
Components of the ECM and their receptors interact 
with virtually all cell types (including the nervous 
system) in embryonic and adult organisms (Reichardt, 
1993) (Figure 5B). Thus, the ECM presently is defind 
to include essentially all secreted molecules that are 
immobilized in the matrix outside of cells. The 
functions of these diverse molecules include inhibition 
of neurite outgrowth, cell migration during 
embryogenesis, modulation of synaptic transmission, 
anti-adhesive activities, growth factor interaction, ECM 
anchoring, binding of proteases and/or protease 
inhibitors, initiation of intracellular signaling cascades, 
cytoskeletal signal transduction and pH modulation of 
Na+/H+ antiporter activity (Reichardt, 1993). 
The cell adhesion molecules (CAMs) mediate cell-cell 
and ECM interactions during embryonic development, 
maintenance of adult tissue architect-ture, the 
inflammatory response, wound healing, and tumor 
metastasis. The adhesion molecules and/or receptors 
thus influence many biological activities and processes 
including cell proliferation, differentiation, cell 
junction formation, and polarity by targeting cell-
surface adhesion to specific ECM proteins/ligands on 
adjacent cells. Multiple families of adhesion 
molecule/receptors have been identified as the 
following: a) the heterodimeric integrin receptors; b) 
the immunoglobulin-like adhesion molecules; c) the 
homophilic cadherin calcium-dependent proteins; d) 
the LEC-CAMs with lectin-like domains; and e) 
homing receptors that target lymphocytes to specific 
lymphoid and nonlymphoid tissues (i.e., CD44) 
(Albelda and Buck, 1990). The finding that cells can 
respond to signal transduction from the ECM via 
integrin receptors is highly significant (Legate et al., 
2009). The signal apparently is transduced through the 
integrins linked to intracellular talin, vinculin, and 
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actinin which transmit to the actin cytoskeleton. 
Extensive signaling "cross-talk" can occur between the 
receptors and other CAMS involving both tyrosine 
kinases and polyphosphoinositide hydrolysis. It is 
thought that induction messages of early immediate 
genes can then be transmitted to the nucleus via actin-
associated cytoskeletal elements (Legate et al., 2009). 
HAFP appears to display multiple adhesive sites of the 
short variety (3-10 AA) in addition to longer sequenc  
homologies to the adhesive molecules themselves 
(Figure 5B). Examination of the primary AA sequence 
structure of HAFP reveals the presence of both RGD 
(AFP AA #271-273) (arginine-glycine-aspartate) and 
LRE (leucine-arginine-glutamate) CAM recognition 
sites (Pierschbacher and Ruoslahti, 1984; Yamada an 
Kennedy, 1985). The RGD functions as a cell-
attachment site within several different extracellular 
matrix glycoproteins including fibronectin, 
thrombospondin, von Willebrand's factor, and 
vitronectin. The LRE triamino sequence (AFP AAs 
213-215) is a crucial determinant for the binding of 
various motoneurons to s-laminin and also serves to 
inhibit neurite axonal outgrowth at synaptic sites 
(Hunter et al., 1991). 
HAFP, as shown in Figure 5B, displays some sequence 
homologies with a multitude of ECM and adhesion 
proteins as detected in the GenBank. Examination of 
the ECM sequence sites identified in the figure 
revealed different matrix-related molecules including 
plasma-secreted, cell surface, basement membrane, 
enzyme, and fibril forms. It can be observed that mny 
AA sequence identities were localized on HAFP 
domain II with lesser sequences on domain I, and fewer 
still on domain I. In fact, the majority of ECM-protein 
homologies resided on domain II. Overall, the AA 
sequence identities ranged from 30% to 47% over 
stretches of 17 to 28 AAs in length, respectively. The 
proteins included collagens, fibrinogen, and thrombtic 
molecules related to clot formation/dissolution, plate et 
attachment, and serine protease activities. It is evident 
that HAFP domain II and to a lesser extent, domain I, 
are associated with ECM activities, which encompass 
hemostasis, basement membrane architecture, fibril 
scaffolding and crossbanding, cytoskeletal attachment, 
and signal transduction. 
The second domain of AFP has short peptide sequences 
common to ECM proteins bearing short sequence 
cellular adhesion motifs (CAMs). These findings 
distinguish AFP from other albuminoid family 
members whose proteins lack the short peptide 
sequence similarities to the ECM protein family 
(laminin, fibronectin, collagen, vitronectin, 
thrombospondin, etc.) of macromolecules (Yamada and 
Kleinman, 1992). Adhesive ECM macromole-cules 
have potential utility in the study of developmental 
stages and disease states involving growth, 
differentiation, cell migration, and tumor metastasis. 
Using synthetic peptides derived from the ECMs, the 
functional significance of such short signal peptide 
sequences has been identified from one or more 
domains of the ECM molecules (Tashiro et al., 1989; 
Nomizu et al., 1993; Tuszynski et al., 1993). Some of 
the CAM-derived synthetic peptides have been found 
to block cell differentiation, tumor growth, and 
angiogenesis (angiostatin). Several ECM proteins 
(laminin, collagen, fibronectin) contain a whole host f 
biologically-active peptide sequences with differing 
activities specific to cell type (Grant et al., 1989). 
Furthermore, the various cellular receptors for a 
particular active site sequence may differ slightly 
among specific cells, permitting a large diversity of 
biological functions and cell regulatory roles. Human 
AFP (especially the second domain) contains many 
short peptide sequences that are common to the ECM-
derived CAMs. Thus, HAFP appears to possess a 
multiplicity of such peptide sequences, which suggests 
involvement in a diverse range of biological activities. 
A variety of cell attachment peptide sequence sites 
from extracellular matrix proteins (see Refs 72-89, 
listed in Figure 5B were compared to human AFP, 
ALB, αALB, and DBP numbered peptide sequences 
(8). Upon inspection of the matched peptide sequences, 
it was observed that AA matches occurred on AFP with
CAM-like sequences in the second domain of AFP (AA 
#212 to 388). Exact AA matches appeared less 
frequently on human ALB and DBP molecules. It 
becomes apparent that: 1) a large number of diverse 
cellular adhesion activities might be involved and; 2) 
AFP shares short sequence similarities with a variety of 
the different CAM segments identified to date. Such a 
diverse array of peptide recognition signals suggests 
that AFP might share functional properties with 
integrin molecules as previously suggested 
(Mizejewski, 1997). However, such capabilities of AFP 
might ultimately depend on its ligand-bound state and
extracellular localization during growth. 
It is of special interest that a periodic spacing of the 
signal recognition ECM peptides is readily observed in 
the second domain of AFP. The first of the known 
peptide signals, LRE, is positioned at the amino-
terminal side of domain two on the HAFP molecule 
(AA #213-215). There follows a gap of approximately 
40 AAs before a second signal peptide (LDV) occurs at 
HAFP AA #260 to 262. It is at this point that a pattern 
of regularity arises. The next four signals (including 
LDV) occur approximately every 10 AA sequences 
from AA #259 to 289, including LDV (fibronectin), 
RGD (fibronectin), DGEK (collagen I, IV), and YICSQ 
(laminin B1). The RGD sequence on AFP may be 
positioned on a tight turn of an exposed loop, as seen 
on the crystal structure of ALB, which is similar to
AFP ((Carter and He, 1990); see Figures 2B and 5). 
The next proposed signal peptide at AFP AA #327 
(PNLDR) is similar to laminin B1, followed by a 
scrambled RGD at AA #334, and a downstream 
sequence at AA #370-375 (ILRVXK) comparable to 
laminin-A. Scrambled RGD is known to be a growth 
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inhibitor sequence, AA #335-337 (Kijimoto-Ochiai and 
Noguchi, 2000). 
Teleologically, it would be important if an abundant 
fetal protein were to possess adhesion recognition 
sequences in its primary structure. Such adhesion 
capabilities would provide a protein with the 
modulatory properties of cell growth and 
differentiation, cellular attachment and migration, 
cytoarchitectural structuring, and morphogenetic cell
movements and migrations during both embryogenesis 
and histogenesis. Examples of such regulation have 
been reported with the integrin family receptors, 
beginning at gastrulation and continuing throughout 
development, involving processes such as neural and 
myoblast movements, sex cell migrations, and neurit 
extension on Schwann's cells (Albelda and Buck, 
1990). In addition, some adhesion molecules (i.e., 
tenascin) are known to consist of both adhesive and 
anti-adhesive intrinsic domains and signal-recognitio  
sites (Spring, 1989). Hence, it would not be surprising 
to identify ECM, adhesion, and anti-adhesion signal-
like AA sequences on different portions of the AFP 
molecule. Such potential AFP matches have been 
detected from computer-derived sequence matching 
data (see Figure 5B). 
C) Enzymes, Fibrin Binding, and Serine Proteases 
Human tissue-type plasminogen activator (TPA) is a 
serine protease enzyme responsible for dissolving 
fibrinogen in blood clots (Banyai et al., 1983). 
Interestingly, an AA sequence site detected on HAFP 
domain I (Figure 5C), located by computer GenBank 
analysis, showed a 35% sequence identity over 20 
residues to γ-fibrinogen (Figure 5B, AA #83-102) and 
antithrombin-III (AA #29-54). Both plasminogen and 
TPA are bound by the fibrin polymer in clots to 
facilitate enzyme: substrate binding alignment. It has 
further been reported that certain human TPA residus 
between AA #20-148 display significant sequence 
peptide corresponding to the last 39 residues at the 
carboxyl terminus (domain III) of HAFP (AA #571-
609) (Baker, 1985). A portion of this segment on TPA 
(AA #82-128) overlaps a region that was previously 
shown on AFP to be related to the epidermal growth 
factor motif module (Gray et al., 1983). TPA identity 
sites have also been detected on HAFP at the border f 
domains II and I. The domain II-I overlap site showed 
32% extending over 19 residues. An NH2-terminal 
portion of TPA sequence (AA #26-62) contains the 
fibrin-binding finger-domains for the serine 
protease/substrate contact and this region of TPA 
resembles HAFP residues 433-461 in the third domain 
of the AFP molecule (Figure 5C). 
Interestingly, the region (AA #423-444) is known to be 
a major hydrophobic binding pocket of HAFP, which 
corresponds to the estrogen-binding site of rodent AFP
(Nishi et al., 1991). Residues crucial for estrogen 
binding on rat AFP are AA #s 428, 430, 433, 434, and
435 (Nishi et al., 1993). Thus, the estrogen binding 
pocket of RAFP may reside along side or overlap a 
portion of a site that could function as a serine protease 
site for binding substrate. If this were the case, AFP 
might bind serine protease substrate and/or inhibitors, 
but not cleave them as was previously proposed (98). 
Indeed, a search of the literature reveals a series of 
reports that are consistent with this hypothesis (refs. 
(Mizejewski et al., 1975; Baker et al., 1978; Scott et al., 
1989; Luscher and Eisenman, 1990a; Mahoney et al., 
1991; Kato et al., 1992; Gehring et al., 1994; Manak, 
1994; Olson and Rosenthal, 1994)). Other enzyme-
related homologies include superoxide dismutase, 
kinesins, tyrosine kinases, cyclin-dependent-kinases, 
ATP binding protein, protein kinases, and many others 
(Figure 5E). 
D) Oncogene Transcription and Expression 
Transcription factors, tumor suppressors, and 
homeodomain proteins. The oncoproteins are nuclear 
phosphoprotein products of the proto-oncogenes, which 
now include ras, rel, myc, myb, fos, jun, ski, ets, cbl, 
erb A, and many others (Luscher and Eisenman, 1990a; 
Secombe et al., 2004). Most oncoproteins were 
determined to be transcription factors, which function 
as molecular switches that sense incoming signals and 
modulate the transcription of specific genes (Lewin, 
1996; Hess et al., 2004). Although predominantly 
localized in the nucleus, they are capable of mediating 
and shuttling specific transcriptional responses to 
signals originally generated in the plasma membrane or 
cytoplasm (Martin, 1991; Bernards and Settleman, 
2009; Montagut and Settleman, 2009; Plentz et al., 
2009; Quinlan and Settleman, 2009; Sharma and 
Settleman, 2009). Some, like myc, are present in nearly 
all cell types, while others like myb, are restricted 
largely to hematopoietic cells (Luscher and Eisenma, 
1990b; Secombe et al., 2004). Many oncoproteins have 
functional partners with which they heterodimerize to 
bind DNA, such as fos and jun, myc and max, etc. Like 
other proteins, the oncoprotein transcription factors are 
synthesized in the cytoplasm and transported into the 
nucleus via a nuclear localization signal within their 
primary structure (Hess et al., 2004; Quinlan and 
Settleman, 2009).  
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Protein-protein and protein-DNA interactions of the 
nuclear oncoproteins are often mediated through helix-
loop-helix and leucine zipper motifs as discussed blow 
(Mizejewski, 1993; Babu et al., 2004). 
Among the transcription factors, the discovery of the 
homeobox gene superfamily that translates the 
homeodomain proteins represents a hallmark discovery 
in embryonic development (Gehring et al., 1994; 
Manak, 1994). These embryonic induction factors have 
long been sought since Hans Speman first speculated 
their existence (induction factors) in the early 1900s. 
First discovered in insects, homeobox proteins and their
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homologs are now known to exist in nematodes, 
rodents, humans, plants, and yeast (Scott et al., 1989). 
Homeo-proteins serve to direct and control pattern/ 
positional body development in embryos concer-ning 
anterior/posterior, trunk-thorax segmentation, 
dorsal/ventral axis, body polarity, neural-tube 
formation, and caudal/gut formation. In fact, birth 
defects are often homeotic transformations (or 
mutations) resulting in developmental anomalies in 
which one part of the body develops in the likeness or 
dissimilarity of another in contrast to bilateral 
symmetry. Pattern formation in the embryonic germ 
layers usually involve a network of feedbacks betwen 
intrinsic programs of gene expression in developing 
precursor cells and extrinsic signals exerted by the 
surrounding embryonic environment (Olson and 
Rosenthal, 1994). The homeotic proteins frequently 
direct or mediate inductive pathways that partition 
early axial germ layers into structures or segments with 
distinct regional identities. These morphogenetic 
processes are then linked to the terminal differentiation 
of that particular germ-layer derivative. Examples of 
the homeodomain proteins would include Pou, 
antennepedia, crumbs, Wnt, Sonic Hedgehog, forkhead, 
and Pax (Manak, 1994) (Figure 5D). 
Since the homeodomain proteins are present during 
early embryogenesis, it would seem reasonable that 
AFP displays short homeodomain sequences in 
molecular mimicry of these pattern-recognition 
regulating proteins. For example, mutations in the Pax-
3 domain result in central nervous disorders relevant to 
AFP such as anencephalies and spina bifida, in addition 
to abnormalities associated with neural crest structu es 
(Mizejewski, 1997). In mammals, Pou domains are 
expressed during early embryogenesis in many regions 
of the developing brain including forebrain and nerve 
cord (Figure 5D). Aside from binding the major groove 
of DNA, the Pou domain is required for homo-and 
heterodimerization of the Pou domain proteins. The Pit-
1 gene of the Pou domain controls development of the 
anterior pituitary and mutations of this gene display 
failure of adenohypophysis development. The Wnt 
(Wingless) gene codes for proteins that are expressed in 
the midbrain-hindbrain border and mutations in this 
gene results in the absence of these brain regions. 
Finally, Crumbs protein mutations have led to sever 
disorganization and degeneration of ectodermally-
derived embryonic epithelia. Thus, it may be more than 
a coincidence that HAFP segments share short AA 
sequence homologies with the homeodomain proteins, 
which are endowed with embryonic body positional 
information. 
Some of the identified transcription factors, tumor 
suppressors, and homeodomain protein sequence 
homologies to HAFP are cataloged in Figure 5D. As 
shown in the figure, AA matching identities for the 
transcription factors (ranging from 29 to 54% over 
lengths from 13 to 24 AA) are found largely in HAFP 
domains I and II. In comparison, the tumor-suppressor 
(retinoblastoma) protein (141) identities appear to 
reside largely on domain I of HAFP. However, a fat-
protein (cadherin-related) site (Mahoney et al., 1991) 
was detected on domain III, demonstrating a 100% AA 
identity over only a 5-AA length. Thirdly, the 
homeodomain proteins are found to exhibit AA 
identities ranging from 41% to 67% over stretches of 
10-27 AA in AFP domains I and II. However, shorter 
stretches of AAs were also detected on domain III 
(67%-100%) including homeodomain signature motif 
that is characterized by only four conserved AAs and
residues in the C-terminal third domain of all 
mammalian homeotic proteins including AFP (Scott et 
al., 1989). Another 8-AA segment of homeotic proteins 
is highly conserved, though not invariant, in stretch s 
of AA that were either amino terminal or carboxyl 
terminal to the homeodomain signature sequences (HS 
in Figure 5D). 
Many oncoproteins have been implicated in the control 
of normal cell growth and proliferation, in cell-cycle 
control, and in apoptosis. In cancer, they may be 
involved with aberrant growth in mutations that 
activate the oncogenic potential of cellular proto-
oncogenes and cause loss of control of normal cellular 
proliferation and differentiation. Such activating 
mutations, as seen in growth-suppressing proteins (p53
and retinoblastoma protein), which bind transcription 
factors, constitute fundamental steps in the 
development of human cancers. Although the precise 
steps in molecular oncogenesis are unknown, mutations 
can inactivate certain oncoprotein properties such as 
nuclear localization, transcriptional activation, 
dimeriza-tion, and DNA binding (Kato et al., 1992). In 
the case of c-erb A (Figures 5H-I), dominant-negative 
mutations can inhibit the transcriptional regulatory 
function of the thyroid hormone receptors, resulting  
a loss of hormone responsiveness and hormone-induced 
differentiation (Damm, 1993). This is comparable to 
the tumor-suppressor genes, where a loss of function 
can induce the transformation process. In this way, 
normal hormone-activated nuclear receptors, such as 
the thyroid and retinoic acid receptors, can function as 
growth suppressors since their differentiated cellular 
targets lose their proliferative potential (Liu et al., 
1995). 
E) Apoptosis (Programmed Cell Death) 
Mammalian development is accomplished by a 
combination of cell proliferation, differentiation, and 
apoptosis or programmed cell death (Figure 5E). 
Apoptosis routinely occurs during embryo-genesis, 
histogenesis, metamorphosis, endocrine-dependent 
tissue atrophy, and normal adult tissue turnover 
(Gerschenson and Rotello, 1992; Cohen, 1993). 
Apoptosis can be readily distinguished from necrosis, a 
condition that results from pathologic injury, 
complement-based cellular attack, severe  
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hypoxia, hyperthermia, lytic viral infection, and toxin 
exposure. Apoptosis is characterized by nuclei 
condensation and segmentation, DNA degradation, 
membrane microvilli loss, and cell surface blebbing.  
Apoptosis occurs naturally in the immune system 
(lymphocytes, thymocytes) induced by antigen-receptor 
complexing or by glucocorti-coid induction (Caron-
Leslie, 1994; Hockenbery, 1994). NKCs or cytotoxic T 
cells also exhibit apoptotic induction in target cells (see 
Figure 5A) and an NKC site overlaps the FAS region 
on HAFP (Figure 5E). Tumor regression is often 
mediated through apoptosis as a result of UV or, X-
irradiation, and chemotherapeutic exposure in cancer 
cells (Nagata, 1994). 
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Throughout mammalian development, and especially in 
the early embryo, a competition exists between cell
death signals and survival (rescue) signals. For 
example, gastrulation in the mouse embryo is 
accomplished by two signals; an apoptotic induction 
that forms the inner cell mass and a rescue (reversal) 
signal that allows the survival of columnar cavity-
lining cells (Lewin, 1996). Although the programmed 
cell death signal occurs in the embryonic inner mass 
cells, the rescue command is thought to be contained 
within the extracellular matrix cells in juxtaposition to 
the ectoderm. It is in this fashion that the embryo forms 
tubes with a single layer of cells lining the lumens. Cell 
death helps to create lumens (cavities) in a variety of 
embryonic structures, with the dead cells engulfed by 
phagocytosis. It has further been shown that the 
integrin receptors of the ECM play a role in regulating 
apoptosis during mammary differentiation in the mouse 
(Lewin, 1996). 
One previous study demonstrated that AFP and AFP-
receptor antibody blocked the induction of apoptosis in 
HL-60 leukemia cells in culture (Laderoute et al., 
1994). The induced cell death by AFP was associated 
with cellular adherence in microtiter plates. Cell death 
was assessed by morphology, shrinkage of dying cells, 
inducibility and reversibility kinetics, and DNA 
fragmentation patterns. Concomitant studies by others 
had already shown that cells cultivated on substrates 
that prevent cell adhesion rapidly progressed into 
apoptosis (Collins, 1987). It has now been ascertained 
that the signal for programmed cell death is mediat 
by a cell-surface transmembrane protein termed the Fas 
antigen belonging to the tumor-necrosis factor/nerve-
growth factor receptor family (Caron-Leslie, 1994). 
Likewise, it has determined that the rescue signal from 
apoptosis is conferred by the cytosplasmic Bcl-2 
protein derived from β-cell leukemias and from 
lymphomas (Hockenbery, 1994). As stated above, a 
delicate balance exists during mammalian development 
regarding cell death and rescue (survival) signals for 
cell growth, proliferation, and differentiation. Hence, it 
should be feasible to detect remnants of both signal 
types on individual growth-regulating proteins such as 
AFP. The elegant studies by Dudich et al. have 
revealed that AFP blocks apoptosis inhibition while 
promoting cell death effectors (caspases) in tumor and 
cell-free systems (Dudich et al., 2000; Semenkova et 
al., 2003; Dudich et al., 2006). 
On the basis of GenBank identification, an AA 
sequence resembling a Fas-like peptide stretch (AA 
#59-86) is readily detectable on domain I (Figure 5E)
of HAFP (39% identity; 23 AA in length). In a similar 
fashion, slightly downstream on domain I of HAFP, a 
sequence stretch identifying with the tumor necrosis 
factor receptor type 1 and TNF (AA #96-120) itself can 
also be discerned (50% identity,  
 
 
12 AA in length). Both stretches of AAs lie in  
juxtaposition to each other on the first domain of 
HAFP. One could speculate that dimerization or 
binding of AFP to these signal proteins could blunt the 
cell-death signal resulting in enhancement or 
continuation of cell growth. In contrast, a 
rescue/survival signal represented by a Bcl-2-like AA 
stretch (AA #476-484) was detected at the amino 
terminal end of HAFP domain III (41%, 19 AA in 
length). Interestingly, this Bcl-2 site is localized 
adjacent to APO-6 (Figure 5E) and near a proposed 
hinge region, which allows rotational flexibility. A 
conformational change in the tertiary structure of AFP, 
possibly induced by ligand binding or shock signal, 
could expose a rescue site (i.e., Bcl-2), which was 
normally hidden in a molecular crevice (Mizejewski et 
al., 1996). As above, one might speculate that 
dimerization or binding of AFP to a Bcl-2 protein could 
block the rescue/survival signal, resulting in the 
induction of cell death. A fetal protein such as AFP 
might be expected to display a FAS-like growth 
enhance-ment (domain I) segment in its normal 
molecular configuration, while a concealed Bcl 2 
interface might surface following a stress-induced 
conforma-tional change. In this fashion, AFP could 
function to enhance growth while conditions conducive 
to stress or shock (heat or glucose shock, hypoxia, 
hyperthermia, excessive ligand exposure) might expose 
a signal site resulting in cessation of growth or cell 
death. In this manner AFP could function in both the
up- and down-regulation of growth by employing a 
binding or dimerizing mechanism to apoptotic 
mediators. Several other proposed apoptosis sites 
labeled APO-1 to 6 are shown in Figure 5E in addition 
to sites of peptide to tumor necrosis factor (TNF) and 
its receptor (TNFR). 
F) Ligand Binding and Carrier/Transport Peptide 
Sites 
There exists overwhelming evidence that AFP is an 
embryonic and fetal carrier/transport molecule for a 
multitude of ligands including fatty acids, bilirubin, 
heavy metals, steroids, retinoids, drugs, dyes, and
antibiotics (Hirano et al., 1984a; Hirano et al., 1984b; 
Hirano et al., 1985). However, the precise binding 
location on the AFP molecule is known for only some 
of those ligands. For example, a major fatty acid-
binding site for long-chain fatty acids has been 
documented to lie between AA #227 and 246 on HAFP 
domain II (Nishihira et al., 1993). Lysine AA #242 
appears to be one of the most essential AAs for this 
fatty acid binding site. Studies employing Scatchard 
binding/saturation analysis had previously 
demonstrated that at least three possible ALB binding 
sites (Ka = 10
-7 M, n = 3) exist for the polyunsaturated 
fatty acids (i.e., arachidonic and decosohexanoic acids) 
(Parmelee et al., 1978; Aussel and Masseyeff, 1983).  
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If AFP is similar to ALB in this regard, then it is 
probable that one fatty acid-binding site exists on each 
of the three domains, and such may indeed be the case 
(Reed, 1986). The remaining two fatty acid-binding 
locations can be proposed on the basis of GenBank-
derived AA comparisons to fatty acid-related proteins.  
One such example of a proposed HAFP domain I  
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site (AA #60-79) could reside adjacent to AA-residues 
55-88 that shows an AA peptide to fatty acid synthetas  
(28% identity, 32 AA). A proposed folic acid binding 
site is also proposed to occur at this position (AA #64-
75). A second possible site on domain I could reside at 
AA #189-222, wherein lies another fatty acid protein-
like stretch (32% identity, 19 AA in length) togethr 
with a Vitamin-D binding site. On domain II, a fatty 
acid denaturase homolog site was identified on AA 
#242-256 overlapping the confirmed fatty acid-binding 
site at AA #227-246. The third AFP binding site resid  
on domain III (AA #437-460) and appears to overlap 
the estrogen-binding site homologous to rat AFP 
according to previous competitive-binding reports 
(Benassayag et al., 1979; Mizejewski, 1995b). 
The estrogen-binding interface on rodent AFP has been 
determined to occupy a region between AA #438 to 
452 (human AFP AA #445-459) forming an α-helix 
segment lying adjacent to a β-sheet/turn structure 
extending from residues 464 and 498 (Nishi et al., 
1991; Nishi et al., 1993). The former site represent  a 
major hydrophobic binding pocket on HAFP that binds 
little or few estrogenic steroids, in contrast to the 
rodents (Swartz and Soloff, 1974). In humans, a high 
affinity E2-binding region (AAs 445-459) displays 
overlapping binding sites for fatty acids, 
diethylstibesterol (DES), protease inhibitors/substrates, 
retinoids, warfarin, coumarin, phenylbutazone, 
pyrazolic drugs, and anthranilic acid (Hirano et al., 
1984a, 1985). A low affinity E2 binding site on HAFP 
extends from AA #464 to 498 (Vakharia and 
Mizejewski, 2000). Competitive-binding studies 
employing rat AFP determined that estrogen was 
indeed bound on RAFP domain III together with 
retinoids and fatty acids (Aoyagi, 1979). 
Employing competitive inhibition-binding analysis, it 
was determined that bilirubin did not compete with 
fatty acids for the same binding sites on HAFP, and
both sites were totally distinct from the retinoid-
binding region (Aoyagi, 1979; Hirano et al., 1984b; 
Bansal, 1990). Earlier studies had already ascertain d 
that HAFP possessed two separate binding sites for 
bilirubin while ALB has three sites for this heme 
pigment (Berde et al., 1979). The former study 
concluded that HAFP bound both fatty acid and 
bilirubin noncompe-titively on domain I and domain II, 
while steroids and retinoids (lesser than fatty acids) 
were bound on domain III (Berde et al., 1979). 
Regarding bilirubin-binding on HAFP, the two sites 
appear to reside on either side of the single tryptophan 
residue on HAFP as determined by spectral and 
competitive-binding analyses. With such data, it can be 
speculated that the location of the two bilirubin bding 
regions in light of GenBank AA identities. The domain 
I site could be positioned in the amino-terminal 
direction to the tryptophan (present at AA #181)  
 
between AA #176 to 186. At this position, HAFP AA 
identities were found with pigment-associated proteins 
(β-globin, 40%, 20 AA in length; chloroplast protein, 
35%, 29 AA in length). In comparison, the domain II 
site might be located in the carboxy-terminal direction 
to the tryptophan residue and to the proposed fatty 
acid-binding site. The second bilirubin site is proposed 
to lie between AA #282 and 290, where Vitamin-D and 
pigment-related protein AA identities were also 
detected (heme oxygenase, 33%, 12-AA length; 
cytochrome-c oxidase, 82%, 11-AA length; a 
chloroplast protein, 46%, 13-AA length; and 
phycoerythrin, 58% identity, 19-AA length). HAFP has 
been shown to bind to heme (Zizkovsky et al., 1983) 
and that binding could occur at this latter site. I may be 
of interest that a benzodiazepine receptor peptide s te 
(Figure 5H) has also been identified at this same region 
(AA identity 38%, 24-AA in length) that also includes 
an adjacent serotonin receptor region at AAs 277-289 
(AA identity 42%, 12-AA length). Both of the latter 
compounds bind nitrogen-ring aromatic hydrocarbons 
that mimic those of bilirubin. In contrast, ALB has 
these latter two binding sites on domain III instead of 
domain II (Kragh-Hansen, 1991). 
The binding sites of heavy metals (Cu2+, Zn2+, Pb2+, 
etc.) on HAFP have only been approximated; however, 
multiple binding sites have been reported (Aoyagi et 
al., 1978; Wu et al., 1987), in accor-dance with AFP 
purification methods using metal-chelated column 
chromatography (Andersson et al., 1987). Early studies 
of ALB binding to heavy metals frequently have 
implicated the first domain (Aoyagi et al., 1978) and 
AFP was found to be similar. Published reports have 
supported the involvement of histidine residues in the 
binding of Cu2+ and Zn2+ ions, probably at the 
imidazole group (Aoyagi et al., 1978; Wu et al., 1987) 
since AFP has been reported to bind tryptophan 
(Ingvarsson and Carlsson, 1978; Baker et al., 1980). 
Cysteine residues have also been implicated with Zn2+
in binding to DNA (Wahli and Martinez, 1991); 
however, HAFP has only two free cysteines, located t 
AA #37 and 86. These residues of free cysteines occur 
in the first domain of HAFP in keeping with the ALB 
metal-binding sites. It may be no mere coincidence that 
HAFP sequence identities with Cu/Zn-superoxide 
dismutase occur at this region (Figure 5C) from AA 
#29 to 54 (31%, 25-AA length) (Figure 5J). A Cu2+-
transporting ATPase identity stretch (26%, 19-AA 
length) was also found between AAs 156 to 175, 
wherein lies an Arg-His-Pro sequence in domain I. On 
the second domain of HAFP, a histidine-rich region 
(Figure 5J) was also found at AA residues #262-270 
that contains three histidines. This site would qualify s 
a Cu2+- and/or Zn2+-binding region since it overlaps a 
Cu2+-transporting ATP identity site (33%; 21-AA 
length) located there (Figure 5F). From these data, one 
could propose that heavy-metal binding can largely b  
assigned to HAFP domains I and II. 
G) AFP Peptide Sites for Hormones and Growth 
Factor Binding 
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Reports of AFP interactions with a variety of hormones 
can readily be found in the literature (see below). Such 
findings include hormones such as  
follicle-stimulating hormone (FSH), luteinizing 
hormone (LH), thyroid hormones, and growth factors. 
Previous studies showed that AFP was indeed subject 
to hormonal, nutritional, and hematological regulation 
(Belanger, 1975). These reports indicated that 
prednisolone, adrenaline, and thyroxine depressed AFP 
through a selective blockade of its synthesis. In the case 
of thyroxine, decrease of AFP synthesis has been 
confirmed both in cell culture studies (Anteby et al.,
1993) and in clinical follow-up of hypothyroid 
newborns (Mizejewski and Pass, 1992). In contrast, 
estradiol (E2) and estrone (E1) treatment induced the 
synthesis of AFP in the livers of adult rodents (Aussel, 
1976; Kotani, 1987). In vitro studies further have 
shown that AFP was capable of inhibiting the 
formation of water-soluble metabolites of E1 and E2 by 
incubation with microsomes from rat livers in the 
presence of NADPH (Aussel, 1976). 
The addition of purified AFP fractions into newborn 
rats bearing E2-sensitive pituitary tumor cells also 
prevented oncogenic growth (Sonnenschein and Soto, 
1979; Sonnenschein et al., 1980). The authors 
concluded that AFP was a specific inhibitor of the 
multiplication of cells that were E2 sensitive for 
growth. Because of such reports, the author of this atlas 
chapter undertook a series of studies to investigate and 
hopefully elucidate the E2-sensitive growth inhibitory 
properties of AFP in vivo (Mizejewski et al., 1983, 
1986; Mizejewski and Warner, 1989; Jacobson et al., 
1990a; Mizejewski et al., 1990; Allen et al., 1993). 
These studies concluded that rodent and human AFP 
contained an encrypted (occult) E2-sensitive growth 
regulatory site that is induced to emerge following 
exposure to high estrogen concentrations (Mizejewski 
et al., 1990; Mizejewski et al., 1996; Vakharia and 
Mizejewski, 2000). Such a site could account for the
prevention of fetal hyperestrinism in the face of high 
maternal estrogen levels during pregnancy as first 
purposed by Vannier and Raynaud (Vannier and 
Raynaud, 1975) and later addressed by Nunez et al. 
(Nunez, 1976; Nunez et al., 1989). It was this hidden 
E2-sensitive growth regulatory site on HAFP that was 
produced and studied as a purified 34-mer peptide 
(Mizejewski et al., 1996). 
Growth enhancement by AFP has long been reported in 
the scientific literature (Mizejewski, 2001a, 2002). The 
question of whether AFP contains bona fide growth 
factor or mitogenic activity was addressed by recent 
reports implicating protein kinase-A pathways (Li et 
al., 2002a). However, the complete mechanism of the 
growth-regulatory properties exhibited by AFP in a 
decade of reports is yet to be fully elucidated. In this 
regard, an AA sequence peptide site related to growth 
hormone (46% over 11 AA) was found on the first 
domain of HAFP (Figure 5H). A previous report had 
demonstrated that purified HAFP, together with 
platelet-derived growth factor, synergistically enha ced 
the proliferative activity of human medullary breast-
carcinoma cell cultures (Leal et al., 1991). It may be 
germane to this report that HAFP displays an AA 
stretch on domain I (Figure 5H) with identity to the 
platelet-derived growth factor-α receptor (29% identity, 
21-AA length). 
The synergistic action of HAFP with various growth 
factors has also been reported in porcine ovarian 
granulose cell cultures. It was initially found that 
physiological levels of HAFP could enhance the 
mitogenic activity of epidermal growth factor (EGF) 
and transforming growth factor-α (TGFα) (domains II 
and III), suggesting that AFP might serve to modulate 
growth factor-mediated proliferation during 
development and neoplasia (Leal et al., 1990; Keel et 
al., 1991). Further studies on these porcine cell cultures 
revealed that AFP in the presence of EGF plus insuli -
like growth factor-α1 (IGF-α1) and platelet-derived 
growth factor (PDGF) also produced the growth-
enhancing effect (Keel et al., 1991). It may be of 
interest that a PDGF receptor-like sequence has been
detected on the first domain of HAFP and IGF sites 
were found on domain II and III (Figure 5H). 
Subsequent use of the granulosal cell cultures seemed 
to indicate that, while HAFP was capable of growth 
factor-enhanced growth of these cells in vitro, HAFP 
also inhibited the steroidogenic function of E2 
production (Keel et al., 1992). It was later 
demonstrated that HAFP actually inhibited the FSH-
stimulated E2 production in the porcine granulosa cells 
(Keel, 1993). Those authors suggested that AFP could 
be inhibiting differentia-ted functions such as 
aromatase enzyme activity while enhancing cell 
proliferation. It could be speculated that the FSH-like 
sequence shown in Figure 5H may have relevance to 
this observation. It is readily observed in Figure 5G that 
a large variety of hormone and growth factor peptide 
sites are present representing reproductive, growth, and 
metabolic moieties. 
H) G-Protein Coupled Receptor Signaling 
Unlike cytoplasmic signaling, G-protein signaling 
cascades begin at a cell surface heptahelical receptor 
(Figure 3, Panel-1). The G-proteins are heterotrimeric 
peripheral membrane proteins, anchored to the 
basolateral portion of the cell membrane by both 
intrinsic hydrophobicity and by lipid modifications 
(prenylation) of their subunits,  
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largely the α and γ types (Lefkowitz, 2000). The G-
proteins connect to the seven-transmembrane 
(heptahelical) receptors of the cell membrane that, in 
turn, affects downstream signaling pathways via 
protein-to-protein scaffold interaction (see 
(Mizejewski, 2002)). The G-protein coupled receptor 
(GPCR) activation (by ligand binding) triggers the 
exchange of GTP for GDP by the Gα subunit, of the 
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heterotrimeric G-protein complex; this induces a 
conformational change in the Gα subunit which 
facilitates its dissociation from the receptor and the Gα 
subunits that bind and activate downstream effector 
pathways (Foord and Marshall, 1999; Lefkowitz, 
2000). 
The heptahelical receptors, which become linked to G-
proteins, interact with extracellular receptor kinases 
(ERKs) and adaptor proteins responding to 
neurotransmitter, hormonal, light, taste, odorant, and 
growth factor stimulation (Lefkowitz, 2000) (see 
Figure 5H). Signal transduction of this type can be 
uncoupled by a physiological process termed "agonist 
desensitization" (Katragadda et al., 2001). In this 
process, a blunting of the second messenger responses 
occurs following prolonged or excessive agonist 
stimulation (Bockaert and Pin, 1999). Following 
agonist binding to the cell surface GPCRs, endocytosed 
clathrin-coated receptosomes are generated 
(Mizejewski, 2001b). The endocytotic clathrin-induced 
pathway recruits a G-protein-associated adapter protein 
termed arrestin and the mechano-enzyme, dynamin 
(Freedman and Lefkowitz, 1996; Bunemann, 1999). 
Arrestin binding to the receptor uncouples the G-
proteins from the pathway so that no further kinase 
phosphorylation cascades can occur (Clark et al., 1999; 
Oakley et al., 1999; McNiven et al., 2000). Clathrin is 
bound by arrestin and assisted by dynamin in 
trafficking the receptosome protein/peptide cargo to 
either an endosome or proteosome destination. The 
dyamin enzyme mediates the fission (vesicle pinching-
off) step subsequent to the initial coated-pit formation 
in the membrane vesicle recycling process (McNiven et 
al., 2000). However, rapidly repeated agonist 
stimulation depletes the cell surface receptor population 
(without subsequent replacement), which renders the 
cell insensitive to further stimulation. 
Receptor blockade, which is related to agonist 
desensitization, can occur when a decoy agonist ligand 
binds to the receptor and the signal is insufficient to 
induce the proper conformational change needed to 
activate the cell surface receptor to bind the G-proteins; 
this deprives further ligand binding to the GPCR (Clark 
et al., 1999; Oakley et al., 1999). AFP and its derived 
peptides might be able to desensitize or quench the 
GPCR signal transduction pathways and functionally 
impair the cellular growth response of multiple cell 
types, including tumor cells. Examples in Figure 5H
include a multitude of receptors in domains II and III. 
Thus, AFP and other protein-derived peptides could 
serve as decoy ligands for GPCR, they would bind to 
the receptors but would not induce subsequent ERK-
protein cascade interactions. In turn, this could induce a 
refractory state in the mitogenic response to MAPK 
interactions in the G-coupled pathway that regulates 
downstream mitogenic activities. Such a pathway 
would  
represent a non-activating ligand occupancy of the 
GPCR, thereby depriving the cell of further signal 
transduction as previously demonstrated (Krupnick et 
al., 1997; Ghanouni et al., 2001). The various G-protein 
coupled cell surface receptor peptide sites displayed in 
Figure 5H include those for serotonin, thyroid, 
benzodiazepine, platelet-derived growth factor, 
epidermal growth factor, fibroblast growth factor, 
somatostatin, and acetylcholine. 
I) Heterodimerization and Nuclear Localization 
Signal Sites 
Leucine zipper motif. In order for AFP to influence 
growth positively or negatively at the transcription 
level, one possible mechanism might involve 
heterodimerization with nuclear receptors or nuclear 
accessory proteins via a leucine (repeat) zipper-lik  
motif in the ligand-binding domain. Such motifs have 
been previously proposed and reported for AFP 
(Mizejewski, 1993; Dauphinee and Mizejewski, 2002). 
The carboxy-terminal third domain of murine AFP is 
known to include an estrogen-binding region as well as 
retinoic acid-, thyroxine- and fatty acid-binding site  
(Hsia et al., 1980; Herve et al., 1982; Aussel and 
Masseyeff, 1984). The estrogen-binding region in 
rodent AFP has been identified and mapped to the 
amino-terminal side of the third domain (AA #420-506, 
high affinity region 447-480, low affinity) (Nishi et al., 
1991) just downstream from a known 'hinge' region. A 
putative leucine zipper motif appears to be located 
downstream (toward the carboxy terminus) from the 
ligand (E2)-binding site. Indeed, such a series of nine 
sequential heptad repeats have been described 
(Mizejewski, 1993), beginning with AA #515 in human 
AFP. All nine heptad repeats extend from AA 515 to 
606 in human AFP and are presented in Figure 5I. 
Many of the postulated requirements for these motifs to 
qualify for heptad eligibility appear to be satisfied 
within the third domain of both mammalian species of 
AFP. These proposed criteria state that positions 1 and 
8 of the heptad repeat contain one of the following 
hydrophobic AAs: leucine (Leu), methionine (Met), 
isoleucine (Ile), valine (Val) or phenylalanine (Phe). 
The fifth position in the heptad contains either 
hydrophobic residues or the charged AAs, arginine 
(Arg) or glutamic acid (Glu). The AAs listed above at 
heptad positions 1, 5, and 8 are especially well 
conserved among the nuclear receptors, particularly the 
T3R, VDR and RAR receptors (Wahli and Martinez, 
1991). As described by Forman et al. (Forman et al., 
1989) and Landschulz et al. (Landschulz et al., 1988), 
the folding of the well-conserved 1, 5, and 8 positi ns 
of the heptad into coiled-coil helices (see below) would 
result in alignment along the same surface of the DNA 
helix for dimerization. 
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The nine heptads described for human AFP were 
aligned by computer analysis with the nine heptads 
proposed for the Group II receptor superfamily 
members, which include the VDR, RAR, T3R, erb-α2, 
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V-erb and REV-erb receptors (see Figure 5I and list of 
abbreviations). Although attempts to align the entir  
third domain of either AFP with any individual receptor 
proved unsuccessful, notable matching of AAs between 
AFP and Group II receptor members was observed on 
an individual heptad-to-heptad comparison, when 
analyzed by computer AA matching and alignment 
(Hitachi HIBIO-PROSIS Protein Input and Analysis 
software). The most conserved AA matching occurred 
between Group-II nuclear receptors and heptads 1, 2 
and 5, (58-61%), while heptads 3, 4, 6, 7, and 9 showed 
48-54%, and heptad 8 showed 41%. Computer analysis 
demonstrated that the most conservative matching 
(58%) occurred between AFP and the retinoic acid 
receptors (α, β and γ), followed next by the erb series 
(51%) and the thyroid (α1, β) (50%) receptors and 
finally the vitamin D receptors (42%) (Figure 5F). 
It was next determined whether certain stretches within 
the nine-heptad AFP dimerization motif could be 
matched to members of the remaining steroid/thyroid 
superfamily consensus region in the ligand-binding 
domain was identified where both a dimerization and 
DNA-binding/stabilizing site colocalized (Fawell et al., 
1990). Subsequent alignment of this superfamily 
dimerization region with the nine heptads proposed for 
AFP revealed a conserved AA region which matched to 
AFP heptads 3 through 7 (Figure 5I). Thus, these 
matching data demonstrated AA sequence peptide with 
five of the nine AFP heptads to both the steroid an the 
thyroid members of the superfamily. The analysis again 
confirmed (see above) that the retinoic acid receptors 
displayed the highest AA peptide (60%) in the 
dimerization region among the superfamily members. 
Interestingly, the GR displayed the highest peptide 
among the steroid receptors. The entire superfamily 
displayed the following pattern: RAR>GR>PR>ER, 
ERR>nur, VDR, MR>T3R>AR>COUP>ear. Thus, 
human AFP could possess a motif in the ligand-binding 
domain which might engage in both dimerization 
activities and stabilization of receptor binding to the 
DNA helix. 
Transcription-associated proteins (TAPs), which 
interact with activated receptors, have been described 
as transcription co-factors or auxiliary proteins, many 
of which have yet to be characterized (Bourguet et al., 
2000; Love et al., 2000); indeed, AFP might function as 
such a factor. A highly conserved 30-AA region, 
bearing a TAP heterodimerization motif in many 
members of the receptor superfamily, has reportedly 
been localized to the ligand-binding subdomain of 
nuclear receptors (Spanjaard et al., 1991). Indeed, such 
a TAP-like binding region can likewise be visualized in 
a carboxyterminal region in juxtaposition to the stroid-
binding subdomain reported for AFP, namely HAFP 
(AA #464-496). Alignment of these respective AAs in 
AFP with a broad spectrum of nuclear receptors (NR) 
and transcription-associated factors revealed 
identify/similarity matching of AAs (Figure 5D). On 
HAFP AA#464-496, the nuclear receptor superfamily 
displayed the following gradation pattern of AA heptad 
matching: RAR>RXR>ER>T3R. 
A second and third TAP-binding region of the T3R, 
located in the second domain of AFP, consists of 15-24 
AA juxtaposed to the ligand binding region (E receptor 
domain) which is conserved in all members of the c-
erbA superfamily (O'Donnell et al., 1991). It is shown 
in Figure-5D that these potential transcription-
associated segments are displayed in the second 
domain of human AFP at AA #242-256 and AA #358-
381. Total AA identify/similarity between AFP and the 
steroid/ thyroid receptors ranged form 40-80%. The 
steroid receptor peptide in this region could be 
attributed to the reported observation that this region of 
the ER has been implicated in the binding of the HSP-
90 and HSP-70 to the ER (Pratt et al., 1988). 
Nuclear localization signals (NLS): 
Various NLSs are found in various members of the 
steroid/thyroid/vitamin receptor superfamily (Dang and 
Lee, 1989; Guiochon-Mantel et al., 1989; Picard et al., 
1990); these were then compared to presumptive signal 
AA cassette sites proposed for the AFP molecule. It 
became immediately apparent that the AFP molecule 
itself displayed intrinsic prototypic signal-like squence 
homologies among its own three domains (Figure 5I). 
There further appeared to be multiples of the different 
signal types on all three domains of AFP. The NLSs 
have been divided into three groups as follows: 
First, four compact type of signal-like cassettes present 
on all three domains of AFP appeared to resemble 
those of the thyroid/retinoic acid receptors more than 
the steroid receptor family members, although both 
share similarities (Picard et al., 1990). 
Second, two signal sites within the AFP steroid binding 
domain bore resemblance to comparable bipartite 
proto-signal sites reported for the steroid nuclear 
receptor members (LaCasse et al., 1993). 
Third, two NLS sites appeared to comprise part of a 
more degenerative signal sequence, one site of which 
lies on the second domain of AFP (Horowitz et al., 
1989). 
The NLS-type-1 would correspond to the D-domain of 
most steroid receptors and might be exemplified on 
AFP as AA #339-354 in which a series of basic 
compact, concise AAs reside at AA #341-345. The 
NLS-type-2 region of the glucocorticoid receptor 
contains two subregions that require hormone-binding 
for activation, one located toward the amino-end of the 
ligand binding domain and the other at the carboxy-
terminal last third of the domain. These two NLS 
regions on the glucocorticoid receptor might be 
analogous to the proposed protosignal AA #416-431 
and AA #465-478 on AFP. In the glucocorticoid 
receptor, these regions of the ligand binding domain 
required hormone for activation; thus, it may be more 
than  
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coincidence that AFP AA #416-431 and AA #465-478 
lie at the beginning and end of the estrogen binding 
subdomain reported for rodent AFP (Nishi et al., 1991). 
The latter proto-signal which appeared to be present at 
AFP AA #465-478 lies directly in a region crucial to 
steroid (estrogen) binding regula-tion in the third 
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domain of AFP (Nishi et al., 1991). These two regions 
on AFP could serve as potential proto-signals for 
organelle (nuclear) accumulation as reported for the 
glucocorticoid, estrogen and progesterone receptors 
(Picard and Yamamoto, 1987; LaCasse et al., 1993). 
A compact (concise) signal in the third domain of 
human AFP might be located within AA #537-562 
which lie in a strongly hydrophobic region of leucine 
zipper-like heptad repeats resembling a stretch of 100 
AAs comprising a large putative dimerization 
subdomain found in the nuclear receptor superfamily 
(Mizejewski, 1993). AFP is known to undergo a 
conformational change in the presence of high E2 
concentrations, as evidenced by a change in the UV 
difference spectrum (Jacobson et al., 1990b). The 
estrogen receptor contains an estrogen-induced proto-
NLS-type-2 in addition to three other basic AA-rich 
proto-signals which cooperate following exposure to 
estrogen (Ylikomi et al., 1992). Thus, AFP might 
mimic the estrogen receptor in displaying multiple 
weaker (degenerative) signal-like sites (AA #416-431, 
465-478; Figure 5I). A fourth suspected NLS of the 
estrogen receptor, although more degenerative, exists 
toward the amino terminal side of the DNA binding 
domain. Such discontinuous motifs are known to exist 
in other superfamily members (such as retinoic acid, 
thyroid, retinoic-X and mineralo-corticoid receptors) 
(Horowitz et al., 1989; LaCasse et al., 1993), and AFP 
may indeed have such a degenerative NLS-like site at 
AA sequences 223-237. Other degenerative (type-3) 
presumptive sites on the first domain of AFP at AA 
#80-94, 102-116 and 142-156 could also serve as 
presumptive signals for other organelle targeting. 
It may be no coincidence that one of the proposed 
signal cassette sites on AFP (AAs 532-545; Figure 5I) 
is associated with a presumptive hetero-dimerization 
region which was previously proposed for HAFP 
(Mizejewski, 1993). Since the nuclear targeting escort 
proteins usually recognize a targeting signal, it would 
seem reasonable to find (as in AFP) the dimerization 
sites located in the near vicinity, either flanking the 
signal cassette or inclusive with it. This observation 
would suggest a direct association between the 
presence of the signal cassette and the location of the 
dimerization interface. It would be conceivable that 
NLS sites on proteins also function as dimerization 
recognition and/or docking sites (Smith and Toft, 
1993). 
J) Amino Acid-Rich Repeat Sites 
The HAFP molecule contains AA-rich repeat sites 
which include clustered multiples of glycine, proline, 
histidine, and alanine in its AA sequence. An 
interesting AA repeat is found at AA #455-5600 found 
as AAT and AAT (Figure 5J). The alanine AAs are 
known to be anti-freeze motifs in fish proteins (Lin et 
al., 1999). One of the three glycine-rich regions is 
located on domain I at AA #77-85 while the remaining 
two on domain III at AA #473-482 and AA #492-498. 
Glycine is usually found as an AA chain component in 
beta sheet turns. A histidine-rich region was found o  
domain II at AA #263-271 suggestive of zinc and 
cobalt binding sites. Proline-rich regions on AFP were 
found at five regions namely, AA #131-144 (domain I); 
AA #172-177 (domain I); AA #323-328 (domain II); 
AA #492-498 (domain II); and AA #521-524 (domain 
III). Prolines are known to serve as helix-breakers and 
are also involved in Src-3(Ser/Thr kinase)-peptide sit s 
(Nguyen et al., 1998). Various regions of basic AA 
(BAS sites) residues such as lysine, arginine, histidine, 
can be observed at AA #168-176 (domain I); AA #245-
249 (domain II; AA #437-439 (domain III, and AA 
#283-488 (domain III). In comparison to the basic AAs, 
the acidic AAs, such as glutamic and aspartic acids 
(GASR sites), are seen at AA #96-107 (domain I); AA 
#149-156 (domain I); AA #388-400 (domain II); AA 
#565-573 (domain III; Figure-5J); and AA #587-595 
(domain III). The acidic AA sequences stretches are 
often affiliated with proteins that bind to nuclear 
receptor/heat shock protein complexes such as HSP70 
and HSP90 (Pratt et al., 1988). Two disease-related 
sites are located at AA #279 to 293 which are rich in 
glutamic acid/glutamate; these diseases states are 
Huntington's and Sjorgren's syndromes. 
K) The Cytoskeletal Proteins, Intermediate 
Filaments, and Microtubule Peptide Sites 
Actin, an abundant intracellular protein, is known to 
circulate at micromolar concentrations in peri-pheral 
blood (Mc Leod et al., 1989). In mammals 
experiencing diverse forms of tissue injury, actin is 
released from dying cells and may be entrapped in 
fibrin clots adjacent to or directly at tissue damage 
sites. Actin has been reported to be a noncompe-titiv  
inhibitor of the clot-dissolving enzyme, plasmin (Lind 
and Smith, 1991). Adult plasma reportedly contains 
two high-affinity actin-binding proteins (i.e., vitamin 
D-binding protein [Gc globulin] and plasma gelsolin), 
which serve as actin-sequestering agents to protect 
against micro-vascular damage. Thymosin also serves 
as a major actin-sequestering protein in cells 
(Nachmias, 1993). Within the cell itself, actin is a 
dominant, abundant cytoskeletal protein existing in 
monomeric, filamentous, and protein-complexed forms. 
Profilin, also a major intracellular protein, binds 
monomeric G-actin to constitute an intra-cellular pool 
of nonfilamentous actin (McWhirter and Wang, 1993; 
Mizejewski, 1997). The profilin-actin complex is called 
profilactin and serves as an intracellular repository f 
available actin. Previous reports have demonstrated that 
actin can inhibit plasmin's hydrolysis of substrate, 
suggesting that accessible lysine residues of actin 
interact with the kringle fingers (lysine-binding 
regions) of the plasmin molecule (Lind and Smith, 
1991). The authors of the latter study suggested that 
extra-cellular-released actin may modulate plasmin-
dependent biological responses. 
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Since AFP does possess a putative actin-binding site 
(Mizejewski, 1997), other physiological and 
pathological spin-off functions might be tenable. For 
example, an actin-binding function contributes to cell 
transformation in the Philadelphia-chromo-some-
positive human leukemias (McWhirter and Wang, 
1993). The BCR-Abl oncoprotein complex, if 
prevented from binding F-actin, showed a reduced 
ability to transform rat fibroblasts, which mimic 
leukemia cell transformation. While BCR activates the
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Abl tyrosine kinase, the presence of both an actin-
binding and a DNA-binding domain on the Abl proto-
oncogene product suggests that the protein is capable of 
relaying a signal from the cytoskeleton to the genome 
in a single step. The actin-binding state of the oncogene 
transformation induces a redistribution of dispersed 
intracellular F-actin into punctate aggregates 
surrounding the cell nucleus (McWhirter and Wang, 
1993). This process has been proposed to interfere with 
the normal  
signal transduction pathways by disrupting inter-
actions between the actin cytoskeleton and growth 
factor/cell adhesion receptors at the plasma mem-brane. 
It would be logical to implicate AFP in such actin-
coupled growth regulatory signal pathways in view of 
the association of AFP with growth, differentiation, 
regeneration, cell transformations, and cellular 
adhesion as discussed below. 
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HAFP appears to further display short AA segment 
homologies (identities) to the cytoskeletal proteins that 
could aid in the further elucidation of AFP function 
based on structural analysis (Figure 5K). These proteins 
include the actin-associated filaments, the motor and
microfilaments, and the intermediate filaments 
(Pollard, 1993). These stretches of HAFP AAs, 
extracted from GenBank, are displayed in Figure 5K.
After partitioning of the cytoskeletal proteins into their 
three classes, certain trends and/or patterns emergd. 
First, the actin-associated proteins' identities appe r to 
be clustered largely on domain II of HAFP. In contras , 
the microfibril and motor filament (myosin) AA 
identities are amassed on HAFP domain I. Finally, the 
intermediate-filament protein homologies are more 
widely distributed, being found mainly on domains I 
and II. However, it is of interest that AA sequence 
identities of two anchor proteins namely, ankyrin and 
catenin, were both localized at the carboxy-terminal 
domain of HAFP. These computer sequence peptide 
findings would suggest a trend where certain areas on 
the HAFP molecule might conceivably provide a 
dimerization interface for interaction with actin, 
myosin, and the intermediate filaments. Such surface 
interactions with actin/myosin would implicate muscle 
contraction, cytokinesis, cytoplasmic streaming, 
ameboid motion, and cross-linking with the 
intermediate filaments. The synthesis of AFP has 
further been reported in neonatal rat skin implants 
(Mujoo et al., 1983), but has yet to be confirmed. The 
elevated AFP levels reported in infants with functional 
and dystrophic epidermolysis bullosa, aplasia cutis 
congenita, and epidermolysis bullosa letalis (Dolan et 
al., 1993; Drugan et al., 1995; Gerber et al., 1995) attest 
to a possible linkage between AFP and skin 
intermediate filaments. In fact, it has been suggested 
that AFP screening would obviate the need for fetal 
skin sampling in the prenatal diagnosis of these 
disorders (Gerber et al., 1995). 
L) The Chemokine-like Peptide Sites 
Chemokines are chemical attractant cytokines that 
mediate the migration of cells, i.e. leukocytes, into and 
out of tissues and are essential to the immune response 
and inflammatory reactions (Moser et al., 2004). The 
chemokine gene family is composed of four member 
groups based on the amino-terminal positioning of their 
cysteine (C) AAs (Nakayama et al., 2003). The four 
member family of chemokine peptides (60-90 AA in 
length) are divided and subgrouped as follows: Group I 
has a single cysteine (C) residue in the amino terminus 
of the molecule; Group II has a CC grouping; Group III 
has the CXC configuration; and Group IV has the 
CX3C sequence where X is any AA residue (see top 
portion of Figure 5L). The chemokines are the ligands 
(binding agents) that bind to heptahelical receptors; 
these receptor molecules weave through the cell 
membrane seven times as transmembrane (TM) 
domains. Chemokines and their receptors are highly 
conserved in nature being present in mammals, birds, 
reptiles, amphibians and fish, and they share AA 
similarities across species. 
Chemokines are produced locally in tissues and direct 
the emigration and immigration of cells from the 
bloodstream into sites of inflammation, infection, and 
cell proliferation. Chemokines can direct and influence 
many physiological processes such as angiogenesis, 
degranulation, autoimmunity, HIV infection, tumor 
growth, parasite infection, and leukocyte trafficking 
(Robledo et al., 2001). Discovered less than 20 years 
ago, the chemokines are now known to function as 
regulatory molecules in cell maturation, trafficking, 
homing, and the development of various tissues 
(Robledo et al., 2001). The chemokines are now known 
to comprise a family of nearly 50 ligands and 20 
receptors, which despite its size, is remarkably 
homogeneous with properties similar to IL-8, the first 
chemokine to be discovered. Many chemokines are 
secreted as a result of pathological conditions, some 
fulfill regulatory roles, and others function in cell 
migration during histo- and organogenesis and in 
cancer metastasis. Chemokines attracted much attention 
when it was discovered that some of their receptors 
function as binding sites for the HIV virus that causes 
AIDS (Orsini et al., 1999). Although they show 
receptor binding with HIV, their main function is 
attracting, homing, regulating, and luring cells into 
tissue parenchyma (Verani and Lusso, 2002). 
Full-length AFP, produced during pregnancies of all 
mammals, has long been associated with hematopoiesis 
in the fetal liver. Indeed, studies have shown fetal AFP 
is positively correlated with fetal hemoglobin while 
negatively correlated with red blood cell levels, 
hematocrit, and erythropoietin/transferring 
concentrations (Bartha et al., 1999). Thus, AFP has 
long been implicated in erythropoiesis myelopoiesis 
(bone marrow) and lymphopoiesis during pregnancy. 
These two latter developmental states are now known 
to be regulated by the chemokines. By means of 
GenBank AA sequence matching, it was discovered 
that HAFP resembles a segment of the chemokines, 
especially the Group-II (CC) members, GROα, MiP-
1B, Eotaxin, Rantes, and MCP-1 chemokine (Figure 
5L). It is proposed from AA matching evidence that 
portions of HAFP may possess the properties of 
chemokine fragments or appear as chemokine-
mimicking proteins (peptides); see Figure 5L for the 
chemokine comparisons and AFP-matched identities. 
Note in Figure 5L that AFP cysteine bridge clusters 
resemble those of the CC-chemokine ligands. However, 
the chemokine-like homologies appear to be restricted 
to the third domain of AFP beginning at the amino-
terminal portion of that domain (Figure 5L). 
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Full-length HAFP has been reported to bind to the 
CCR5 receptor (Atemezem et al., 2002; Kellner and 
Mizejewski, 2004). In effect, this would cause 
suppression in growth factor-stimulated cells such as in 
prostate and breast cancers as well as HIV cell fusion 
and infection, suggesting that AFP might mimic the 
CCR5 ligand. Thus, it might be possible that AFP 
mimics a cc-chemokine and binds to a cc-chemokine 
receptor, induces the receptor conformational change 
and tubulin (or actin) polymerization; in other cases, it 
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might inhibit cell migration (spreading), cell adhesion, 
and cell proliferation. In other words, AFP may be a 
partial agonist/antagonist chemokine mimic depending 
on its intravascular and interstitial concentrations and 
duration of exposure. Also, AFP would have an 
advantage over the other chemokine-related inhibitors, 
in that other chemokines cannot act in a decoy ligand 
fashion. It could be speculated that AFP could serve as 
a novel type of chemokine inhibitor, in that, it could 
still retain the growth regulatory properties, but still be 
able to induce some of the early (initial) functions of a 
true chemokine ligand (such as immunostimulation). 
Overall, AFP might be useful in pathological situations 
in which chemokines usually are involved. Such 
conditions could include cancer therapeutics, HIV 
infection and transmission, inflammatory diseases, 
angiogenesis, autoimmune diseases, atherosclerosis, 
multiple sclerosis, diabetes, lung infections (as in CF), 
malaria, endometriosis, graft rejection, wound healing, 
and other conditions yet to be discerned. Certainly, 
neurodegenerative dementias such as Alzheimer's 
disease might be viable candidate diseases. 
VI. Concluding Remarks 
At the start of this atlas chapter, it was stated that he 
many biological roles of AFP have yet to be clarified. 
In the face of such a challenge, the in vitro 
carrier/transport ligand-binding function was one of the 
first functions to be demonstrated. A growth-regulatory 
role for AFP, although not yet clearly understood, has 
also been established. The immu-noregulatory 
properties of AFP are still at the threshold of new 
discoveries regarding the use of peptide epitopes in 
hepatoma cancer (vaccine) therapy. AFP is not merely 
a fetal substitute for albumin since ALB is present in 
nearly all vertebrate classes together with a-ALB, but
true AFP is present largely in mammals, and a closely-
related molecule has been identified in birds (Mangum 
et al., 2005). In contrast, true AFP is not present in 
shark, rays, fish, amphibians, salamanders, and reptiles 
(McLeod and Cooke, 1989). The 75 kD shark AFP 
reported by Gitlin (1973) turned out to be alpha-
albumin, not AFP (Mizejewski, 1995a). Moreover, only 
two short stretches of mammalian AFP are nearly 
identical to various mammalian ALBs studied to date 
(Moro and Villacampa, 1986). One is located on HAFP 
domain II (16 AA long) and the other is on HAFP 
domain III (17 AA long). The domain I site resides in a 
region of platelet-surface proteins, while the domain III 
site is localized in an area with high peptide to 
glutathione peroxidase (58% over 31 AA) (see 
(Mizejewski, 1997)). Clearly, both regions appear to 
display functions common to albumin. 
The present atlas chapter was intended to focus on AFP 
as a biologic response modifier in order to expand the 
reader's perspective regarding the functional roles f 
AFP. By amassing a collection of publications in the 
biomedical literature, attempts were made to associate 
computer peptide-derived analyses of AFP domains, 
subdomains, and motifs/cassettes with previously 
published reports regarding the physiological roles of 
AFP. Although the computer findings did not always 
have a published counterpart, numerous insights were 
uncovered to provide both a rationale and justification 
for further studies of AFP physiology based on domain 
and subdomain peptide structure. More intense future 
investigations into the function-al roles of AFP should 
prove mutually beneficial to both the biomedical 
community as well as the biotechnology industry. The 
separation, synthesis, and recombinant production of 
AFP subdomains and sequence fragments could 
provide a novel source of unique or modified 
pharmaceutical derivatives of AFP fragments for 
diagnosis and therapy in such diverse fields as 
endocrinology, hematology, immunology, and 
neurology. 
If only a small proportion of the AA sequence identities 
currently displayed on AFP have real biological 
relevance, this atlas report should provide a deep 
insight into the pathophysiology of AFP. For example, 
if the GenBank-detected sequences were present only 
in the pre- or pro-form of the protein precursor, then 
AFP might have the potential of binding and/or 
dimerizing with that intracellular precursor form of that 
molecule in question. In theory, this might suppress 
formation of the mature protein, thereby depleting its 
intracellular concentration. As presented in previous 
reviews by the author, AFP probably engages in 
different functions at various time points during 
ontogenetic development (Mizejewski, 1985; 
Mizejewski, 1997, 2001a). Conceptually, the binding of 
various ligands to AFP during the progressive stages of 
such development might dictate the specific function of 
AFP at that particular moment during development. 
AFP function could also be determined by various 
environmental factors in the fetal body's internal milieu 
such as ligand concentration, hyper- or hypoxia, pH 
state, blood sugar (glucose) concentrations, blood-gas 
partial pressure, osmolality, and plasma alcohol and
lipoprotein/lipid content. Such conditions have been 
shown to produce conformational transition forms in 
AFP that alter tertiary form and shape (Mizejewski, 
1995a). Many conformational changes are known to be 
reversible and gradual, after which AFP could revert to 
its original form (Mizejewski, 1995a). During these 
transitional changes, sequence sites concealed in 
molecular crevices on AFP might be exposed during 
the environmental stress period and then subsequently 
retract into their concealed state following protein 
refolding (see (Vakharia and Mizejewski, 2000)). In 
this manner, different AA sequence stretches normally 
unavailable might be exposed at various times 
dependent on the environmental shock or distress 
during that parti-cular interval. AFP might contain 
multiple such buried sites in reserve in order to meet a 
variety of developmental challenges to the fetal 
environment. Hence, AFP could serve as a "protein for 
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all seasons" and as the "molecular duct tape" of 
ontogenetic development. 
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